Polaryx Therapeutics said its shares will start trading on the Nasdaq Capital Market on Monday under the "PLYX" symbol.
The clinical-stage biotech firm said it is developing therapies for rare orphan lysosomal storage disorders.
Maxim Group acted as the financial advisor to the company for the direct listing, the firm said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.